G17 OEM

Gastrin-17 (G-17) is applied for the screening, risk stratification, and auxiliary diagnosis of chronic atrophic gastritis, gastric antral mucosal atrophy, and gastric cancer, as well as the non-invasive monitoring of gastric acid status, Helicobacter pylori (H. pylori) infection, and long-term proton pump inhibitor (PPI) therapy. G17 OEM kit utilizes a two-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific monoclonal antibodies target distinct structural epitopes on the G-17 molecule to capture serum or plasma G-17, delivering high sensitivity and exceptional specificity without cross-reactivity to other gastrin isoforms or cholecystokinin (CCK). Calibrated with high-purity recombinant G-17 antigen, the assay provides accurate, reliable, and stable quantitative results. Serving as a crucial non-invasive biomarker for gastric antral secretory function, when combined with PG I, PG II, and the PGI/PGII ratio (PGR) in the "serological gastric biopsy" panel, it supports precise location-specific identification of gastric mucosal lesions, non-invasive gastric cancer risk stratification, and dynamic clinical management.   ★Bulk reagents are available with matching raw materials.